Open Access

Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235

  • Authors:
    • Xiaoyu Yang
    • Bingxuan Niu
    • Libo Wang
    • Meiling Chen
    • Xiaochun Kang
    • Luonan Wang
    • Yinghua Ji
    • Jiateng Zhong
  • View Affiliations

  • Published online on: May 17, 2016     https://doi.org/10.3892/ol.2016.4590
  • Pages: 102-106
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway performs a central role in tumorigenesis and is constitutively activated in many malignancies. As a novel dual PI3K/mTOR inhibitor currently undergoing evaluation in a phase I/II clinical trial, NVP‑BEZ235 indicates a significant antitumor efficacy in diverse solid tumors, including colorectal cancer (CRC). Autophagy is a catabolic process that maintains cellular homeostasis and reduces diverse stresses through lysosomal recycling of the unnecessary and damaged cell components. This process is also observed to antagonize the antitumor efficacy of PI3K/mTOR inhibitor agents such as NVP‑BEZ235, via apoptosis inhibition. In the present study, we investigated anti‑proliferative and apoptosis‑inducing ability of NVP‑BEZ235 in SW480 cells and the crosstalk between autophagy and apoptosis in SW480 cells treated with NVP‑BEZ235 in combination with an autophagy inhibitor. The results revealed that, NVP‑BEZ235 effectively inhibit the growth of SW480 cells by targeting the PI3K/mTOR signaling pathway and induced apoptosis. The inhibition of autophagy with 3-methyladenine or chloroquine inhibitors in combination with NVP-BEZ235 in SW480 cells enhanced the apoptotic rate as componets to NVP‑BEZ235 alone. In conclusion, the findings provide a rationale for chemotherapy targeting the PI3K/mTOR signaling pathway presenting a potential therapeutic strategy to enhance the efficacy of dual PI3K/mTOR inhibitor NVP‑BEZ235 in combination with an autophagy inhibitor in CRC treatment and treatment of other tumors.
View Figures
View References

Related Articles

Journal Cover

July 2016
Volume 12 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Yang, X., Niu, B., Wang, L., Chen, M., Kang, X., Wang, L. ... Zhong, J. (2016). Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Oncology Letters, 12, 102-106. https://doi.org/10.3892/ol.2016.4590
MLA
Yang, X., Niu, B., Wang, L., Chen, M., Kang, X., Wang, L., Ji, Y., Zhong, J."Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235". Oncology Letters 12.1 (2016): 102-106.
Chicago
Yang, X., Niu, B., Wang, L., Chen, M., Kang, X., Wang, L., Ji, Y., Zhong, J."Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235". Oncology Letters 12, no. 1 (2016): 102-106. https://doi.org/10.3892/ol.2016.4590